IP Library Patent Application 11604390
Patent Application
App. No. 11/604,390

Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and ribose

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/604,390
Abstract

A health food/dietary supplement is disclosed suitable for enhancing muscular energy metabolism, comprising as its characterizing active ingredits an alkanoyl L-carnitine and ribose.

Claims (201)

1 . A food/dietary supplement in the form of tablets, capsules, lozenges, pills, granulates, creams, syrups or drops which comprises the following characterizing ingredients:

(a) an alkanoyl L-carnitine selected from the group consisting of isovaleryl L-carnitine, and propionyl L-carnitine or the pharmacologically acceptable salts thereof or mixtures thereof; and

(b) ribose or a phosphorylate derivative thereof

wherein the weight ratio of ingredients (a):(b) ranges from 1:1 to 1:10.

2 . The supplement of claim 1 which further comprises vitamins, sugars, coenzymes, mineral substances, aminoacids, peptides and antioxidants.

3 . The supplement of claim 2 wherein the pharmacologically acceptable salt is selected from the group consisting of chloride; bromide; iodide; aspartate, acid aspartate; citrate, acid citrate; tartrate; phosphate, acid phosphate; fumarate, acid fumarate; glycerophosphate; glucose phosphate; lactate; maleate, acid maleate; mucate; orotate; oxalate; acid oxalate; sulphate, acid sulphate; trichloroacetate; trifluoroacetate and methane sulphonate.

4 . A food/dietary supplement in the form of tablets, capsules, lozenges, pills, granulates, creams, syrups or drops which comprises the following characterizing ingredients:

(a) an alkanoyl L-carnitine selected from the group consisting of isovaleryl L-carnitine, and propionyl L-carnitine or the pharmacologically acceptable salts thereof or mixtures thereof;

(b) ribose or a phosphorylate derivative thereof, and

(c) a carnitine selected from the group comprising L-carnitine, acetyl L-carnitine, butyryl L-carnitine and valeryl L-carnitine or the pharmacologically acceptable salts or mixtures thereof;

wherein the weight ratio of ingredients (a):(b):(c) ranges from 1:1 to 1:10:2.

5 . The supplement of claim 4 which further comprises vitamins, sugars, coenzymes, mineral substances, aminoacids, peptides and antioxidants.

6 . The supplement of claim 4 wherein the pharmacologically acceptable salt is selected from the group consisting of chloride; bromide; iodide; aspartate, acid aspartate; citrate, acid citrate; tartrate; phosphate, acid phosphate; fumarate, acid fumarate; glycerophosphate; glucose phosphate; lactate; maleate, acid maleate; mucate; orotate; oxalate; acid oxalate; sulphate, acid sulphate; trichloroacetate; trifluoroacetate and methane sulphonate.

7 . The supplement of claim 4 , in unit dosage form, comprising:

Propionyl L-carnitine

125 mg

Acetyl L-carnitine

125 mg

L-carnitine

125 mg

Isovaleryl L-carnitine

125 mg

Ribose

500 mg

8 . The supplement of claim 4 , in unit dosage form, comprising:

Propionyl L-carnitine

250

mg

Acetyl L-carnitine

250

mg

Isovaleryl L-carnitine

250

mg

L-carnitine

250

mg

Ribose

2

g

Ribonucleic acid

100

mg

Deoxyribonucleic acid

100

mg

9 . The supplement of claim 4 , in unit dosage form, comprising:

Propionyl L-carnitine

250

mg

Acetyl L-carnitine

250

mg

Isovaleryl L-carnitine

250

mg

L-carnitine

250

mg

Ribose

2

g

L-glutamine

100

mg

L-alanine

100

mg

L-arginine

100

mg

L-glicine

100

mg

L-histidine

100

mg

L-isoleucine

100

mg

L-phenylalanine

50

mg

L-threonine

50

mg

L-serine

100

mg

10 . The supplement of claim 4 , in unit dosage form, comprising:

Propionyl L-carnitine

250

mg

Acetyl L-carnitine

250

mg

Isovaleryl L-carnitine

250

mg

L-carnitine

250

mg

Ribose

1

g

Glucose-1,6-diphosphate

200

mg

Fructose-1,6-diphosphate

200

mg

Galactose-1,6-phosphate

200

mg

Glycerol-3-phosphate

200

mg

Phosphenylpyruvate

100

mg

Thiamine pyrophosphate

5

mg

Pyridoxal-5-phosphate

5

mg

Magnesium stearate

2

mg

11 . The supplement of claim 4 , in unit dosage form, comprising:

Propionyl L-carnitine

250

mg

Acetil L-carnitine

250

mg

Isovaleryl L-carnitine

250

mg

L-carnitine

250

mg

Ribose

1

g

Vit. A

1250

U.I.

Vit. B 1

0.5

mg

Vit. B 6

30

mg

Vit. C

50

mg

Vit. E

5

mg

Nicotinamide

25

mg

Vit. B 12

100

mcg

Vit. D

100

U.I.

Pantothenic acid

30

mg

Magnesium glycinate

5

mg

Manganese

1

mg

L-Selenomethionine

50

mcg

Molybdenum

10

mcg

Zinc

1

mg

12 . A method for the treatment of states of myocardial or skeletal muscle anoxia occurring in coronary or post-infarct disorders or during prolonged physical activity and muscle fatigue, which comprises administering to an individual in need thereof a combination composition comprising the following ingredients:

(a) an alkanoyl L-carnitine selected from the group consisting of isovaleryl L-carnitine, propionyl L-carnitine or the pharmacologically acceptable salts thereof or mixtures thereof, and

(b) ribose or a phosphorylate derivative thereof.

13 . A method for the treatment of states of myocardial or skeletal muscle dysfunction related to conditions of anoxia or insufficient energy supply as occurring in coronary or post-infarct disorders or during prolonged physical activity and muscle fatigue, which comprises administering to an individual in need thereof a combination composition comprising the following ingredients:

(a) an alkanoyl L-carnitine selected from the group consisting of isovaleryl L-carnitine, propionyl L-carnitine or the pharmacologically acceptable salts thereof or mixtures thereof, and

(b) ribose or a phosphorylate derivative thereof.

14 . A method for the treatment of states of myocardial or skeletal muscle anoxia occurring in coronary or post-infarct disorders or during prolonged physical activity and muscle fatigue, which comprises administering to an individual in need thereof a combination composition comprising the following ingredients:

(a) an alkanoyl L-carnitine selected from the group consisting of isovaleryl L-carnitine, propionyl L-carnitine or the pharmacologically acceptable salts thereof or mixtures thereof,

(b) ribose or a phosphorylate derivative thereof, and

(c) a carnitine selected from the group comprising L-carnitine, acetyl L-carnitine, butyryl L-carnitine and valeryl L-carnitine or the pharmacologically acceptable salts or mixtures thereof.

15 . A method for the treatment of states of myocardial or skeletal muscle dysfunction related to conditions of anoxia or insufficient energy supply as occurring in coronary or post-infarct disorders or during prolonged physical activity and muscle fatigue, which comprises administering to an individual in need thereof a combination composition comprising the following ingredients:

(a) an alkanoyl L-carnitine selected from the group consisting of isovaleryl L-carnitine, propionyl L-carnitine or the pharmacologically acceptable salts thereof or mixtures thereof,

(b) ribose or a phosphorylate derivative thereof, and

(c) a carnitine selected from the group comprising L-carnitine, acetyl L-carnitine, butyryl L-carnitine and valeryl L-carnitine or the pharmacologically acceptable salts or mixtures thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2007
From: PIETRO, POLA
To: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
Reel/Frame 018872/0150 →